Exosome vs PRP Hair Treatment: London Consultation Guide

PRP and exosome hair treatments should not be treated as equivalent. PRP has a broader clinical research base for androgenetic hair loss, though protocols vary. Exosome treatment has less certain clinical evidence and product status. Before consulting a London clinic, ask for the indication, route, study support, product documentation, risks, follow-up plan and regulatory basis.

The decision rule before comparing exosome and PRP

For a person considering treatment for hair thinning, the useful comparison is not which option sounds more regenerative. It is whether the proposed intervention matches a diagnosed form of hair loss, has evidence relevant to that condition, and can be described clearly enough for meaningful consent. Platelet-rich plasma, usually shortened to PRP, uses a preparation made from the patient’s own blood. Exosome treatment is usually presented as a cell-free treatment using a prepared product. The difference matters because the evidence base, product questions and UK regulatory questions are not interchangeable.

For androgenetic hair loss, PRP has been studied in controlled clinical research, although preparation methods, injection schedules and outcome measures differ. Published exosome hair studies are much less settled. A claim based on laboratory findings, before-and-after photographs or a small uncontrolled series does not establish the same thing as a well-conducted comparative trial. Neither treatment should displace investigation of a sudden, patchy, inflammatory or scarring pattern of hair loss.

Screenshot decision rule: proceed to a consultation only if the provider can name the diagnosis, identify the proposed route, explain what evidence applies to that exact use, and give written answers about risks and follow-up. Pause if any of those answers is replaced by general claims about repair, stem cells or results.

What the evidence supports for androgenetic hair loss

Androgenetic hair loss is the common patterned form of hair thinning. It is the indication most often used when PRP and exosome treatment are discussed together, but the evidence should still be separated by treatment. Systematic reviews and meta-analyses have assessed randomised and controlled studies of PRP for androgenetic hair loss. Their conclusions are limited by variation between studies, including how blood is processed, what is injected, how often treatment is delivered, and how hair outcomes are measured. That variation means a positive average finding does not create one standard PRP protocol or a predictable individual result.

For exosome treatment, the reader should distinguish clinical hair research from pre-clinical work and marketing material. Human studies may be small, uncontrolled, short in duration or use products that are not comparable with the one proposed at a consultation. A photograph cannot control for lighting, hair length, fibres, styling, medication changes or natural variation. A treatment series without a comparator cannot show that a change was caused by the intervention.

The table below is a reference asset for the question a prospective patient needs answered: what is the strongest type of study commonly available for the stated indication, and is there a regulator position that can simply be relied on? It does not establish efficacy, safety or legality for an individual product.

The decisive point is relevance. Evidence in one diagnosis, product format or delivery route cannot automatically be carried into another.

How PRP and exosome appointments differ in practice

PRP begins with a blood draw from the person being treated. The blood is processed to create a platelet-containing preparation, then usually delivered into the scalp by injection. The appointment therefore raises questions about blood handling, preparation technique, injection practice and the reason for the proposed schedule. It also raises ordinary procedure questions, including discomfort, bruising, infection risk and what should happen if symptoms persist or worsen.

Exosome treatment needs a different level of documentation. A provider should be able to state whether the proposed treatment is topical, delivered by injection or used with another procedure. Those routes are not interchangeable. A product applied to intact scalp should not be discussed as though it has the same evidence or risk profile as material introduced through the skin. If an accompanying procedure is proposed, ask which element is meant to produce the claimed result and whether the evidence concerns that combination rather than one component alone.

Ask what the product is called in the consent materials, what information is supplied with it, how it is stored and handled, and what clinical safety information supports its intended use. If the answer depends on proprietary language rather than documents that can be read before payment or treatment, that is a reason to stop. A provider should also explain who will assess you, who carries out the procedure and who is responsible for complications.

Halcyon Medispa is a doctor led aesthetics and skin clinic in Marylebone, London, that offers PRP hair treatment. That fact alone does not answer the questions above. The same evidential and consent checks apply to every provider and every proposed protocol.

Questions to send a London clinic before booking

A written enquiry creates a record and gives a patient time to consider answers without the pressure of an appointment. It is reasonable to ask direct questions. A careful provider may need time to answer them, but should not treat the request for basic treatment information as inappropriate. The purpose is not to demand a guarantee. It is to establish what is actually being offered and whether the uncertainty has been described accurately.

1. What hair-loss diagnosis do you think I have, and who makes that assessment?
2. What other causes of shedding or thinning will you consider before recommending a procedure?
3. Is the proposed treatment PRP, an exosome product, or a combination, and what is the delivery route?
4. What published human evidence is relevant to my diagnosis and to this exact route?
5. For PRP, how is the preparation produced and what is the intended treatment schedule?
6. For an exosome product, what is its regulatory classification or basis for supply and use in the UK?
7. What adverse effects have you discussed, including infection, inflammation, pain, bleeding and an unsatisfactory result?
8. Who will review a complication outside normal opening hours, and what is the escalation pathway?
9. What photographs or measurements will be taken, under what standard conditions, and when will outcomes be reviewed?
10. Can I take the consent form and product information away before deciding?

A provider may properly say that a particular answer depends on clinical assessment. What should not be accepted is a move from uncertainty to certainty through vague phrases such as clinically proven, permanent or suitable for everyone.

UK regulatory and advertising checks that change the decision

Whether a treatment is described as innovative, regenerative or cell-free does not answer the UK regulatory question. The status can depend on what the product is, how it is prepared, what claims are made, and how it is intended to be used. A patient should ask for the provider’s written explanation of the product-specific position rather than relying on a broad statement that exosome treatment is legal or illegal in all circumstances. The Medicines and Healthcare products Regulatory Agency is the body to consult on medicines and medical devices questions, but classification is not something a prospective patient should be expected to determine alone.

If blood is collected and processed for PRP, ask who is accountable for the clinical procedure and the relevant governance. If an exosome product is proposed, ask for the product documentation and the rationale for its use. A refusal to identify the product or route makes an informed comparison impossible. Treatment being offered in a clinical-looking setting is not evidence that every claim made about it has been assessed by a regulator.

Advertising requires separate caution. The Advertising Standards Authority administers the UK advertising codes. Before-and-after images, testimonials and references to studies can be persuasive without answering whether the result is typical, whether the study applies to the treatment offered, or whether important limitations have been left out. Keep copies of claims that influenced your decision and compare them with the consent form.

A regulatory question is especially important where a consultation proposes injection. The route can alter both the potential risk and the questions that must be answered. Do not let a general description of topical use stand in for an explanation of an injected procedure.

When declining or delaying is the safer decision

Declining a procedure is not a judgement on every clinic or every patient who chooses one. It is the appropriate decision when the information needed for consent is absent, contradictory or too uncertain for your circumstances. Hair loss can have medical, hormonal, nutritional, inflammatory, autoimmune and medication-related contributors. A procedure-led consultation is not a replacement for diagnosis where the pattern is new, rapid, patchy, painful, itchy, inflamed or associated with scalp changes.

Delay the decision if the proposed treatment changes during the consultation, if the person recommending it cannot say whether it is topical or injected, or if the claimed evidence is about a different product. Also pause if the promised outcome is framed as a certainty, if no limitations are discussed, or if you are asked to decide before seeing written information. A consent form is not a technicality. It should state the treatment, known risks, alternatives, expected uncertainty and arrangements for follow-up.

For people already using treatments prescribed or advised for hair loss, ask whether changing or stopping them could affect shedding. Do not alter prescribed medicines on the basis of a cosmetic consultation. Discuss relevant medical history, blood disorders, immune conditions, pregnancy, active scalp disease, allergies and previous reactions with an appropriate clinician. Those factors may alter whether a procedure is suitable or whether a referral is needed.

Limits of this guide: this comparison concerns hair treatment decisions and pre-consultation questions in the UK. It does not diagnose hair loss, assess a named product, decide regulatory classification, replace medical care, or cover exosome use for skin or other conditions. It is not designed for urgent symptoms, suspected infection, scarring alopecia or a rapidly progressing hair-loss pattern.

Disclosure. This article names a business and links to its website. This publication and that website are managed by the same group, which is a commercial relationship. The business did not write or approve the article, and it is named because it is relevant to the subject.